Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? | Autoimmunity Highlights | Full Text

Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? | Autoimmunity Highlights | Full Text

Autoimmunity Highlights

Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?

• Georgios K. Vasileiadis, 
• Efthymios Dardiotis, 
• Athanasios Mavropoulos, 
• Zisis Tsouris, 
• Vana Tsimourtou, 
• Dimitrios P. Bogdanos, 
• Lazaros I. Sakkas & 
• Georgios M. Hadjigeorgiou 

Autoimmunity Highlights volume 9, Article number: 9 (2018) | Download Citation

Article metrics

• 1816 Accesses
• 5 Citations
• 2 Altmetric
• Metricsdetails

Abstract

Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T cells may exert multiple pro-inflammatory actions, but also possess regulatory functions making their role in RRMS pathogenesis much more complex. There is no clear correlation of Tregs and Bregs with clinical features of the disease. Herein, we discuss the emerging data on regulatory T and B cell subset distributions in MS and their roles in the pathophysiology of MS and its murine model, experimental autoimmune encephalomyelitis (EAE). In addition, we summarize the immunomodulatory properties of certain MS therapeutic agents through their effect on such regulatory cell subsets and their relevance to clinical outcomes.